$NBP News

HC Wainwright & Co. Reiterates Buy on NovaBridge Biosciences, Maintains $9 Price Target

NovaBridge Biosciences (NBP) Q2 2026 Earnings Call Transcript

NovaBridge Biosciences H1 EPS $(0.33) Misses $(0.14) Estimate

NovaBridge: Rebranded, Repackaged, But Far From De-Risked

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

NovaBridge Names Srishti Gupta CEO As Sean Fu Steps Down

NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer

NovaBridge Biosciences Says FDA Grants Fast Track Designation To Givastomig In First-Line HER2-Negative Metastatic Gastric Cancer

Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth

NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference

NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value

NovaBridge Biosciences Appoints Mark Hagler As President And Chief Commercial Officer

NovaBridge's Givastomig Could Drive A Major Re-Rating

HC Wainwright & Co. Reiterates Buy on NovaBridge Biosciences, Maintains $9 Price Target

NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration - Slideshow

HC Wainwright & Co. Reiterates Buy on NovaBridge Biosciences, Maintains $9 Price Target

NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

NovaBridge Biosciences Secures FDA Alignment For Accelerated Approval Pathway For Givastomig In 1L HER2-, CLDN18.2+, PD-L1+ GEC Patients